Amgen (NASDAQ: AMGN) announced that CVS Health (NYSE:CVS) will provide preferred access to Repatha® (evolocumab) through its CVS/caremark commercial formularies. "Ensuring access to Repatha for ...
Amgen Inc. (NASDAQ:AMGN) reported that Repatha reduced the risk of all-cause mortality by 20% in a prespecified secondary analysis of the Phase 3 VESALIUS-CV trial. The study enrolled more than 12,000 ...
To view the multimedia assets associated with this release, please click: http://www.multivu.com/players/English/74140513-amgen-repatha-glagov-study. The GLAGOV study ...
An FDA approval for Amgen's cholesterol-reducing Repatha opens its use to for heterozygous familial hypercholesterolemia, a condition that affects 1 in 250 worldwide but often goes undiagnosed.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results